"We are extremely pleased that the FDA granted Fast Track Designation to CUSP06," said Eric Slosberg, PhD, Chief Development Officer of OnCusp Therapeutics. "The early results from our Phase 1 trial ...

DelveInsight's Airway Clearance Devices for Cystic Fibrosis Market Insights report provides the current and forecast market analysis, indiv ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Our BD 2025 strategy has transformed the company into a faster-growing, more profitable organization positioned at the forefront of long-term growth ...

MaxCyte ( NASDAQ: MXCT) Wednesday said that it had entered into a strategic platform license with TG Therapeutics, a fully integrated, commercial-stage, biopharmaceutical company focused on the ...

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...

Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity ... clinical development of stenoparib toward FDA approval in advanced ovarian cancer. With this new phase 2 protocol ...

Allarity Therapeutics, Inc. has announced plans to advance the clinical development of stenoparib, a dual PARP/Wnt pathway inhibitor, for FDA approval in advanced ovarian cancer. The new Phase 2 ...

PONTE VEDRA, Fla., February 06, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular ...

Molecular communications in the bloodstream is a promising area of research, since the bloodstream has the ability to ...

Pham, Chief Executive Officer, Cadrenal Therapeutics, Inc. Dr. Ferguson ... Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted left ventricular ...

--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq ... Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted left ventricular assist devices ...